January 2022 in “Current Enzyme Inhibition” New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.
July 2024 in “Journal of Investigative Dermatology” A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
4 citations
,
November 2024 in “Journal of Advanced Research” Targeting NMMHC IIA may help treat blood-brain barrier damage.
December 2022 in “Small methods” A new hair loss treatment using dissolving microneedles was found to speed up hair growth and was more effective than daily use of common hair growth drugs.
5 citations
,
May 2022 in “Clinical & Experimental Metastasis” Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Hair loss is caused by diet, hormones, and scalp issues, worsened by COVID-19, with treatments like minoxidil and hair transplants available.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Hair loss is caused by nutritional deficiencies, hormonal imbalances, and stress, with treatments like minoxidil and hair transplants available.
September 2024 in “Journal of the American Academy of Dermatology” AH-001 could be a safer and more effective treatment for hair loss.
January 2026 in “ACS Applied Bio Materials” A new treatment using nanoliposomes can improve hair regrowth in androgenetic alopecia.
143 citations
,
May 2002 in “PubMed” LGD1069 effectively prevents breast tumors in mice without toxicity.
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
January 2017 in “Brazilian Journal of Pharmaceutical Sciences” Arteannuin might work against cancer and Alzheimer's by targeting neprilysin.
42 citations
,
August 2012 in “Psychoneuroendocrinology” Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.
2 citations
,
May 2023 in “The Journal of Immunology” NXC736 significantly reduced hair loss in mice with alopecia areata.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
December 2022 in “International Journal of Molecular Sciences” Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.
47 citations
,
November 1982 in “Journal of Cardiovascular Pharmacology” Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.
November 2025 in “The Journal of Dermatology” Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.
March 2024 in “EMBO molecular medicine” Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.
November 2023 in “PubMed” Naringenin and its combination with minoxidil significantly improved hair growth in mice.
21 citations
,
September 2019 in “International Journal of Nanomedicine” RADA16-I can effectively deliver and release mangiferin, improving its solubility and bioavailability.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
April 2023 in “Journal of Investigative Dermatology” ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
42 citations
,
February 1998 in “The Journal of Steroid Biochemistry and Molecular Biology” PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.
10 citations
,
March 2022 in “Healthcare” Mineralocorticoid receptor antagonist therapy does not significantly reduce mortality in COVID-19 patients.
142 citations
,
March 2019 in “Frontiers in Cellular Neuroscience” The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
6 citations
,
September 2015 in “Journal of Medicinal Chemistry” The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.
8 citations
,
July 2024 in “Journal of Advanced Research” CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.